Categories: News

Radius Health to Host Conference Call Today, Wednesday, December 8, 2021

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below:

  • Discuss topline results from the wearABLe Phase 3 trial
  • Review data presented at the San Antonio Breast Cancer Symposium from the EMERALD Phase 3 trial

Conference Call Information:
Domestic Dial-In Number: 1 (866) 323-7965
International Dial-In Number: 1 (346) 406-0961
Conference ID: 7691981

A replay of the conference call will be available on December 8 at 7:00 p.m. ET and a live audio webcast of the call will be archived on the Company’s website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 7691981. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations.

About Radius

Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi Syndrome.

Investor & Media Relations Contact:
Ethan Holdaway
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017

Staff

Recent Posts

Dr. Shahrooz Yazdani Launches $6M Dental Practice Seminar Series to Help Owners Break Free from Burnout

Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…

14 minutes ago

New Aura and UNC-Chapel Hill Study Finds One in Three Kids Have Accessed GenAI Apps

BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…

14 minutes ago

‘Breathable’ Launches to Bring Hope and Humanity Back to Mental Health Care

New online network makes it simple, affordable and stigma-free to connect with licensed therapistsDETROIT, Feb.…

14 minutes ago

Digital X-ray Market worth $7.50 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., Feb. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Digital X-ray Market…

14 minutes ago

mPATH® Health Earns DiMe Seal for Quality and Trust in Digital Health

WINSTON-SALEM, N.C., Feb. 2, 2026 /PRNewswire/ -- mPATH® Health, a digital health company focused on improving…

14 minutes ago

TeachTown Partners with Tulsa Public Schools to Maximize Student Outcomes

WOBURN, Mass., Feb. 2, 2026 /PRNewswire/ -- TeachTown, a leading provider of special education curriculum for…

14 minutes ago